Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

NCT03215810 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer
Metastatic Non-small Cell Lung Cancer
Squamous Cell Carcinoma
Advanced NSCLC
Adenosquamous Carcinoma
Adenocarcinomas

Interventions

PROCEDURE: Tumor-infiltrating Lymphocytes (TIL)
DRUG: Nivolumab
DRUG: Cyclophosphamide
DRUG: Fludarabine
OTHER: Tumor-infiltrating Lymphocyte Therapy
DRUG: Interleukin-2 (IL2)

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]